Actively Recruiting
3D Ultrasound Myocardial Mechanical Wave Measurements
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-11-18
40
Participants Needed
2
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary mitral regurgitation (MR) is a frequent disease that can ultimately lead to heart failure. Primary MR represents the second most prevalent cause of cardiac valve surgery in high income countries. Progressive myocardial fibrosis due to chronic volume overload is recognized as a pathophysiological substrate of altered LV function in primary MR. As fibrosis leads to increased myocardial stiffness, ultrasound mechanical wave propagation measurements within the myocardium could provide important clinical information. Natural mechanical wave velocity (MWV) imaging, using High-frame-rate (HFR) echocardiography has emerged as a promising tool to evaluate myocardial stiffness. The objective is study is to evaluate the correlation between the LV myocardial stiffness (as assessed by 3D ultrasound myocardial MWV mapping) and myocardial interstitial fibrosis as measured using CMR (myocardial extracellular volume measure)
CONDITIONS
Official Title
3D Ultrasound Myocardial Mechanical Wave Measurements
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Severe primary mitral regurgitation patients with effective regurgitation orifice area 240 mm and class I indication for surgery (symptoms and/or altered left ventricular function) (n=10 patients)
- Severe primary mitral regurgitation patients with effective regurgitation orifice area 240 mm without class I indication for surgery (n=20 patients)
- Mild to moderate primary mitral regurgitation patients with effective regurgitation orifice area between 20 mm and less than 40 mm (n=10 patients)
You will not qualify if you...
- Permanent atrial fibrillation
- Acute primary severe mitral regurgitation
- Secondary mitral regurgitation
- Previous cardiac surgery of any kind
- Other severe left sided valvular disease
- Coronary artery disease
- Congenital cardiac disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Pitié Salpêtrière hospital
Paris, Paris, France, 75013
Actively Recruiting
2
Pitié- Salpêtrière hospital (AP-HP)
Paris, Paris, France, 75013
Not Yet Recruiting
Research Team
N
Nadjib Hammoudi, MD, PhD
CONTACT
S
Sebastien Salles, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here